See also

References

1. ^Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041.ISBN 978-3-88763-075-1. Retrieved19 May 2012.
2. ^Buckingham J (1996).Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074.ISBN 978-0-412-54090-5. Retrieved19 May 2012.
3. ^Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013-01-15. p. 3268.ISBN 978-0-8155-1526-5. Retrieved19 May 2012.
4. ^van Dijk J, Hartog J, Hillen FC (1 January 1978)."Non-Tricyclic Antidepressants". In Ellis GP, West GB (eds.).Progress in Medicinal Chemistry. Elsevier. p. 284.ISBN 978-0-7204-0655-9. Retrieved19 May 2012.
5. ^Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy".The Journal of International Medical Research.4 (6):435–440.doi:10.1177/030006057600400610.PMID 800383.S2CID 40083513.
6. ^Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine".Pharmacopsychiatry.22 (6):246–249.doi:10.1055/s-2007-1014608.PMID 2616635.S2CID 39693625.